OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 19.84 |
| Open | 19.92 |
| Bid | 19.00 x 100 |
| Ask | 20.00 x 500 |
| Day's Range | 19.62 - 19.98 |
| 52 Week Range | 5.00 - 51.90 |
| Volume | 12,379 |
| Avg. Volume | 41,740 |
| Market Cap | 51.684M |
| Beta | -0.38 |
| PE Ratio (TTM) | 26.85 |
| EPS (TTM) | 0.74 |
| Earnings Date | Mar 14, 2018 - Mar 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE•4 days ago
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT) ("Opiant"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPNT as the Company's latest news hit the wire. On April 18, 2018, the Company, which is a specialty pharmaceutical organization developing pharmacological treatments for addictions, declared that the National Institutes of Health's National Institute on Drug Abuse (NIDA) has granted it an award of approximately $7.4 million for the development of OPNT003 (intranasal nalmefene) for opioid overdose.
- GlobeNewswire•6 days ago
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. “We view this NIDA grant as further validation of the potential for OPNT003 to be an important treatment for opioid overdose, a growing U.S. health epidemic,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Fentanyl was responsible for more overdose deaths (in excess of 20,000) than either heroin or prescription opioids in 2016. Recognizing the evolution of the opioid crisis, the National Institutes of Health has called for the development of stronger, longer-acting overdose reversal products in order to address this next wave of potent synthetic opioids, like fentanyl.
- GlobeNewswire•21 days ago
Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, April 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•last month
Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates
Stock Monitor: Opiant Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free earnings report on HubSpot, Inc. (NYSE: HUBS ). If you want ...
- Zacks Small Cap Research•last month
OPNT: Opiant Developing New Opioid Overdose Treatment
As part of the solution to the problem, the CDC recommends that the federal government “improve access to…overdose-reversing drugs, such as naloxone” and that health departments “increase naloxone distribution to first responders, family and friends, and other community members in affected areas” (CDC). While not a treatment for opioid dependence, health authorities believe that easy access to naloxone is an essential component of battling the ongoing opioid crisis due to its effectiveness in preventing overdose deaths. On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment.
- Reuters•last month
Trump says he is working to lower prescription drug prices
President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. "If you compare our drug prices to other countries in the world, in some cases it's many times higher for the exact same pill or whatever it is, in the exact same package made in the exact same plant," Trump said. Trump made the remarks during a speech in Manchester, New Hampshire that focused on the administration's efforts to battle the nation's opioid addiction crisis.
- Reuters•last month
As U.S. opioid crisis grows, Trump calls for death penalty for dealers
President Donald Trump spelled out in new detail several steps he favors to fight a U.S. epidemic of opioid abuse, including the execution of drug dealers, a proposal that has gained little support from drug abuse and judicial experts. At an event in Manchester, New Hampshire, Trump unveiled an anti-opioid abuse plan, including his death penalty recommendation, new funding for other initiatives and stiffer sentencing laws for drug dealers.
- GlobeNewswire•last month
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
SANTA MONICA, Calif., March 19, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President ...
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
SANTA MONICA, Calif., March 07, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, following the recent approval by its Board ...
- GlobeNewswire•2 months ago
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
SAN DIEGO, Feb. 22, 2018-- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple opioid blockers such ...
- Zacks Small Cap Research•2 months ago
OPNT: Developing Longer-Acting Opioid Overdose Treatment
On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT003 is an intranasal formulation of nalmefene, a naltrexone derivative. The U.S. continues to battle an opioid epidemic.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Based on FDA Feedback, Opiant Intends to Pursue 505 Development Pathway. Opiant Anticipates Submitting an NDA for this Product Candidate in 2020. SANTA MONICA, Calif., Feb. 12, 2018-- Opiant Pharmaceuticals, ...
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
SANTA MONICA, Calif., Feb. 08, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will record a total ...
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Bryn Mawr Bank, Utah Medical Products, Opiant Pharmaceuticals, Whiting Petroleum, International Business Machines, and QUALCOMM — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bryn ...
Associated Press•4 months agoInsider Q&A: Narcan exec talks merits of spray for overdoses
Dr. Roger Crystal's company was struggling to find new uses for an old drug that reverses overdoses. Then the opioid epidemic hit. Naloxone had first gone on sale in 1971 but was injected with a syringe. ...
- Zacks Small Cap Research•4 months ago
OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18
On December 20, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced that it expects to begin receiving 90% of royalty and milestone payments related to the sale of NARCAN® Nasal Spray beginning in the first quarter of 2018. On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones were met.
- Zacks Small Cap Research•4 months ago
OPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal Spray
On December 13, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced financial results for the first quarter of fiscal year (FY) 2018 that ended Oct. 31, 2017. The U.S. continues to battle an opioid crisis nationwide.
Capital Cube•5 months agoOpiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017
Categories: Yahoo FinanceGet free summary analysis Opiant Pharmaceuticals, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Opiant Pharmaceuticals, Inc. – GW Pharmaceuticals PLC Sponsored ADR and Arena Pharmaceuticals, Inc. (GWPH-US and ARNA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)
- Zacks Small Cap Research•6 months ago
OPNT: Looking to Keep Momentum Going into Fiscal 2018
Opiant Pharmaceuticals, Inc. (OPNT) is a specialty pharmaceutical company developing treatments for substance use, eating disorders, and addiction disorders based on the company’s expertise in opioid receptor antagonists. Opiant currently has one FDA approved drug, NARCAN® Nasal Spray, which is marketed by Adapt Pharmaceuticals through an exclusive collaboration. Fiscal 2017 was a transformative year for Opiant, as the company monetized the royalties for NARCAN® Nasal Spray, uplisted to the Nasdaq stock exchange, strengthened the leadership team with the appointment of a new Chief Financial Officer, and announced encouraging Phase 1 data for OPNT002 in Alcohol Use Disorder (AUD).